Merck to test MK-5172 in HCV with daclatasvir
This article was originally published in Scrip
Executive Summary
Add another multi-drug regimen to the long list of hepatitis C virus combination therapies competing for HCV market share: Merck & Co will run a Phase II clinical trial that pairs its NS3/4A protease inhibitor MK-5172 with Bristol-Myers Squibbs' NS5A inhibitor daclatasvir.